Developing cancer therapies to prolong and improve the lives of cancer patients
We are developing a novel biologic which delivers direct anti-tumor activity while enhancing the effectiveness of standard cancer therapies
Modulating sphingolipid metabolism to potentially treat cancer and other diseases where sphingolipid metabolism is disregulated, such as neurodegenerative diseases.
Our unique biologic is designed to modulate sphingolipid metabolism to target metastatic colorectal cancer while simultaneously addressing the neuropathic pain current treatments often cause.
Addressing an unmet need
Colorectal cancer, the second leading cause of death among cancers, is associated with late-stage diagnosis, poor outcomes, and challenging side effects from current treatment options. BXQ-350 has the potential to redefine metastatic colorectal cancer (mCRC) treatment with encouraging Phase 1b/2a data in first line mCRC.
Where new also means different
Bexion Pharmaceuticals is a clinical‑stage biopharmaceutical company advancing a differentiated class of biologic therapy designed to address fundamental mechanisms that enable cancer survival and treatment resistance. The Company’s lead program, BXQ‑350, engages dysregulated sphingolipid metabolism—a core biological axis underlying multiple hallmarks of cancer—with the goal of improving outcomes in patients with advanced solid tumors.
BXQ‑350 targets cancer adaptation by leveraging an analogue of a natural human protein that modulates sphingolipid metabolism, restoring balance to a core survival system that tumors co‑opt to resist therapy and evade natural cell death.
In the Phase 1b/2a study in metastatic colorectal cancer, BXQ‑350 showed encouraging proof‑of‑concept in combination with standard of care, including in patients with poor prognostic features—settings where tumor adaptation is a major driver of treatment failure.